Maze Therapeutics
NASDAQ · MAZE·South San Francisco, CA·Small-cap·Phase 2
Clinical-stage precision-medicine biotech using human-genetics insights and the Compass platform to drug genetic modifiers of disease. Lead asset MZE829 is an oral APOL1 inhibitor for APOL1 kidney disease (Phase 2 HORIZON readout 2026); the pipeline also includes MZE782 for chronic kidney disease and phenylketonuria, plus earlier-stage discovery programs.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Maze Therapeutics Corporate Presentation — April 2026 | Corporate overview | April 15, 2026 | 37 |